Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with enterprise: Evaluation of clinical and vascular outcome

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Severe intracranial arterial stenosis results in more than 10% incidence of stroke and transient ischemic attack. Using undersized angioplasty with off-label closed-cell Enterprise stent may be a feasible alternative option for treating patients with intracranial atherosclerotic disease who fail dual-antiplatelet medical therapy. The results of the authors' study are presented in this paper. Materials and methods: Between January 2013 and July 2014, 24 symptomatic patients with a total of 30 intracranial arterial stenotic lesions refractory to medical therapy, who underwent undersized angioplasty and Enterprise stenting, were retrospectively reviewed in the authors' institution. The results evaluated include technical success rate, clinical outcome measured as modified Rankin Scale at presentation and follow-up, peri-procedural morbidity within 30 days and 1 year, and follow-up vessel patency. Results: Stent deployment was successfully achieved in all stenotic lesions (30/30). Mean pre-stent and post-stent diameter residual stenosis was 81% and 18%, respectively. The peri-procedural complication rate during 30 days after stenting was 10% per lesion (3/30), including intracranial hemorrhage, in-stent thrombosis and ischemic stroke. No further thromboembolic event or complication occurred in any patient more than 30 days after stenting. Modified Rankin scale≤2 was observed in 64% and 83% of patients at initial presentation and follow-up (mean 15.8 months), respectively. Imaging follow-up was available in 17 of 24 patients (70.8%) and 20 of 30 treated lesions (66.6%) with a mean follow-up period of 15.4 months. Only one asymptomatic in-stent restenosis occurred in 20 available lesions (5.0%). Conclusion: This preliminary study suggests that using undersized angioplasty and Enterprise stenting may effectively treat high-degree symptomatic intracranial arterial stenosis with favorable clinical and angiographic outcome.

Original languageEnglish
Pages (from-to)187-195
Number of pages9
JournalInterventional Neuroradiology
Volume22
Issue number2
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Angioplasty
Stents
Blood Vessels
Pathologic Constriction
Stroke
Intracranial Hemorrhages
Transient Ischemic Attack
Thrombosis
Morbidity
Incidence
Therapeutics

Keywords

  • Angioplasty
  • Enterprise
  • Intracranial arterial stenosis
  • Intracranial stent
  • Stroke

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{681e295942f44a9b8fa1a0488c028eee,
title = "Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with enterprise: Evaluation of clinical and vascular outcome",
abstract = "Background: Severe intracranial arterial stenosis results in more than 10{\%} incidence of stroke and transient ischemic attack. Using undersized angioplasty with off-label closed-cell Enterprise stent may be a feasible alternative option for treating patients with intracranial atherosclerotic disease who fail dual-antiplatelet medical therapy. The results of the authors' study are presented in this paper. Materials and methods: Between January 2013 and July 2014, 24 symptomatic patients with a total of 30 intracranial arterial stenotic lesions refractory to medical therapy, who underwent undersized angioplasty and Enterprise stenting, were retrospectively reviewed in the authors' institution. The results evaluated include technical success rate, clinical outcome measured as modified Rankin Scale at presentation and follow-up, peri-procedural morbidity within 30 days and 1 year, and follow-up vessel patency. Results: Stent deployment was successfully achieved in all stenotic lesions (30/30). Mean pre-stent and post-stent diameter residual stenosis was 81{\%} and 18{\%}, respectively. The peri-procedural complication rate during 30 days after stenting was 10{\%} per lesion (3/30), including intracranial hemorrhage, in-stent thrombosis and ischemic stroke. No further thromboembolic event or complication occurred in any patient more than 30 days after stenting. Modified Rankin scale≤2 was observed in 64{\%} and 83{\%} of patients at initial presentation and follow-up (mean 15.8 months), respectively. Imaging follow-up was available in 17 of 24 patients (70.8{\%}) and 20 of 30 treated lesions (66.6{\%}) with a mean follow-up period of 15.4 months. Only one asymptomatic in-stent restenosis occurred in 20 available lesions (5.0{\%}). Conclusion: This preliminary study suggests that using undersized angioplasty and Enterprise stenting may effectively treat high-degree symptomatic intracranial arterial stenosis with favorable clinical and angiographic outcome.",
keywords = "Angioplasty, Enterprise, Intracranial arterial stenosis, Intracranial stent, Stroke",
author = "Lee, {Kun Yu} and Chen, {David Yen Ting} and Hsu, {Hui Ling} and Chi-Jen Chen and Ying-Chi Tseng",
year = "2016",
month = "4",
day = "1",
doi = "10.1177/1591019915609165",
language = "English",
volume = "22",
pages = "187--195",
journal = "Interventional Neuroradiology",
issn = "1123-9344",
publisher = "Centauro srl",
number = "2",

}

TY - JOUR

T1 - Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with enterprise

T2 - Evaluation of clinical and vascular outcome

AU - Lee, Kun Yu

AU - Chen, David Yen Ting

AU - Hsu, Hui Ling

AU - Chen, Chi-Jen

AU - Tseng, Ying-Chi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background: Severe intracranial arterial stenosis results in more than 10% incidence of stroke and transient ischemic attack. Using undersized angioplasty with off-label closed-cell Enterprise stent may be a feasible alternative option for treating patients with intracranial atherosclerotic disease who fail dual-antiplatelet medical therapy. The results of the authors' study are presented in this paper. Materials and methods: Between January 2013 and July 2014, 24 symptomatic patients with a total of 30 intracranial arterial stenotic lesions refractory to medical therapy, who underwent undersized angioplasty and Enterprise stenting, were retrospectively reviewed in the authors' institution. The results evaluated include technical success rate, clinical outcome measured as modified Rankin Scale at presentation and follow-up, peri-procedural morbidity within 30 days and 1 year, and follow-up vessel patency. Results: Stent deployment was successfully achieved in all stenotic lesions (30/30). Mean pre-stent and post-stent diameter residual stenosis was 81% and 18%, respectively. The peri-procedural complication rate during 30 days after stenting was 10% per lesion (3/30), including intracranial hemorrhage, in-stent thrombosis and ischemic stroke. No further thromboembolic event or complication occurred in any patient more than 30 days after stenting. Modified Rankin scale≤2 was observed in 64% and 83% of patients at initial presentation and follow-up (mean 15.8 months), respectively. Imaging follow-up was available in 17 of 24 patients (70.8%) and 20 of 30 treated lesions (66.6%) with a mean follow-up period of 15.4 months. Only one asymptomatic in-stent restenosis occurred in 20 available lesions (5.0%). Conclusion: This preliminary study suggests that using undersized angioplasty and Enterprise stenting may effectively treat high-degree symptomatic intracranial arterial stenosis with favorable clinical and angiographic outcome.

AB - Background: Severe intracranial arterial stenosis results in more than 10% incidence of stroke and transient ischemic attack. Using undersized angioplasty with off-label closed-cell Enterprise stent may be a feasible alternative option for treating patients with intracranial atherosclerotic disease who fail dual-antiplatelet medical therapy. The results of the authors' study are presented in this paper. Materials and methods: Between January 2013 and July 2014, 24 symptomatic patients with a total of 30 intracranial arterial stenotic lesions refractory to medical therapy, who underwent undersized angioplasty and Enterprise stenting, were retrospectively reviewed in the authors' institution. The results evaluated include technical success rate, clinical outcome measured as modified Rankin Scale at presentation and follow-up, peri-procedural morbidity within 30 days and 1 year, and follow-up vessel patency. Results: Stent deployment was successfully achieved in all stenotic lesions (30/30). Mean pre-stent and post-stent diameter residual stenosis was 81% and 18%, respectively. The peri-procedural complication rate during 30 days after stenting was 10% per lesion (3/30), including intracranial hemorrhage, in-stent thrombosis and ischemic stroke. No further thromboembolic event or complication occurred in any patient more than 30 days after stenting. Modified Rankin scale≤2 was observed in 64% and 83% of patients at initial presentation and follow-up (mean 15.8 months), respectively. Imaging follow-up was available in 17 of 24 patients (70.8%) and 20 of 30 treated lesions (66.6%) with a mean follow-up period of 15.4 months. Only one asymptomatic in-stent restenosis occurred in 20 available lesions (5.0%). Conclusion: This preliminary study suggests that using undersized angioplasty and Enterprise stenting may effectively treat high-degree symptomatic intracranial arterial stenosis with favorable clinical and angiographic outcome.

KW - Angioplasty

KW - Enterprise

KW - Intracranial arterial stenosis

KW - Intracranial stent

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84959862328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959862328&partnerID=8YFLogxK

U2 - 10.1177/1591019915609165

DO - 10.1177/1591019915609165

M3 - Article

C2 - 26542728

AN - SCOPUS:84959862328

VL - 22

SP - 187

EP - 195

JO - Interventional Neuroradiology

JF - Interventional Neuroradiology

SN - 1123-9344

IS - 2

ER -